Chris Lau

Chris Lau

InvestorPlace Contributor

Expertise: Technology, Biotech

Expertise:

Technology
Biotech

Education:

Bachelor of Science
Project Management Professional

Awards and Accomplishments:

Top 100 Tipranks 2015-2021

About Chris:

Chris has over two decades of investing experience. He is an Honors B.Sc graduate (with distinction) in Science and Economics. He holds a Project Management Professional designation

Chris focuses on the technology, cyclical, and healthcare sector. He runs a newsletter with speculative Triple-baggers.

His investment strategy is based on finding undervalued stocks trading at a steep discount to their intrinsic value.

Follow Chris on DIY Value Investing.

Recent Articles

Buy Nokia Stock as 5G Evolution Accelerates

By Chris Lau, InvestorPlace Contributor

When Nokia (NYSE:NOK) spiked to close to $4.75 on July 2, longtime investors breathed a sigh of relief. Nokia stock had fallen to the $2.30…

Novavax Stock Has Probably Topped Out Until Successful Clinical Trials

By Chris Lau, InvestorPlace Contributor

Investors are eyeing clinical results later this month and later this year before committing to buying more NVAX stock.

7 Software Stocks Surging Forward  

By Chris Lau, InvestorPlace Contributor

The technology industry is hot but software stocks are the ones to watch after the pandemic changed everything worldwide.

Why Nio Might Be Worth Nearly $20 a Share

By Chris Lau, InvestorPlace Contributor

After the run-up Nio stock over the last few weeks, some investors may be tempted to sell and take profits.

Why Investors Should Take Another Look at Moderna’s Many Advantages

By Chris Lau, InvestorPlace Contributor

After a solid run since starting at the sub-$20 levels at the start of the year, Moderna (NASDAQ:MRNA) continues to attract plenty of buying and…

Load More